Xenetic Biosciences Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform November 13, 2024
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 November 13, 2024
Ph 1 and iMMagine-1 studies of anito-cel in R/R multiple myeloma patients continue to demonstrate durability and a manageable safety profile November 13, 2024
FDA gives clearance to commence Ph 2 trial of leronlimab in patients with R/R MSS CRC November 13, 2024
Type C Meeting granted with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed GBM November 13, 2024
